Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer.
De Rosa C, Iommelli F, De Rosa V, Ercolano G, Sodano F, Tuccillo C, Amato L, Tirino V, Ariano A, Cimmino F, di Guida G, Filosa G, di Liello A, Ciardiello D, Martinelli E, Troiani T, Napolitano S, Martini G, Ciardiello F, Papaccio F, Morgillo F, Della Corte CM. De Rosa C, et al. Among authors: cimmino f. Biomedicines. 2024 Apr 5;12(4):809. doi: 10.3390/biomedicines12040809. Biomedicines. 2024. PMID: 38672164 Free PMC article.
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
Della Corte CM, Fasano M, Ciaramella V, Cimmino F, Cardnell R, Gay CM, Ramkumar K, Diao L, Di Liello R, Viscardi G, Famiglietti V, Ciardiello D, Martini G, Napolitano S, Tuccillo C, Troiani T, Martinelli E, Wang J, Byers L, Morgillo F, Ciardiello F. Della Corte CM, et al. Among authors: cimmino f. J Exp Clin Cancer Res. 2022 Mar 26;41(1):109. doi: 10.1186/s13046-022-02332-2. J Exp Clin Cancer Res. 2022. PMID: 35346313 Free PMC article.
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer.
Fasano M, Della Corte CM, Di Liello R, Barra G, Sparano F, Viscardi G, Iacovino ML, Paragliola F, Famiglietti V, Ciaramella V, Cimmino F, Capasso M, Iolascon A, Sforza V, Morabito A, Maiello E, Ciardiello F, Morgillo F. Fasano M, et al. Among authors: cimmino f. ESMO Open. 2020 Sep;5(5):e000753. doi: 10.1136/esmoopen-2020-000753. ESMO Open. 2020. PMID: 32912860 Free PMC article.
Role of liquid biopsy for thoracic cancers immunotherapy.
Di Liello R, Cimmino F, Simón S, Giunta EF, De Falco V, Martín-Martorell P. Di Liello R, et al. Among authors: cimmino f. Explor Target Antitumor Ther. 2020;1(3):183-199. doi: 10.37349/etat.2020.00012. Epub 2020 Jun 29. Explor Target Antitumor Ther. 2020. PMID: 36046196 Free PMC article. Review.
FGFR1 is a potential therapeutic target in neuroblastoma.
Cimmino F, Montella A, Tirelli M, Avitabile M, Lasorsa VA, Visconte F, Cantalupo S, Maiorino T, De Angelis B, Morini M, Castellano A, Locatelli F, Capasso M, Iolascon A. Cimmino F, et al. Cancer Cell Int. 2022 Apr 29;22(1):174. doi: 10.1186/s12935-022-02587-x. Cancer Cell Int. 2022. PMID: 35488346 Free PMC article.
Impact of interleukin-6 -174 G>C gene promoter polymorphism on neuroblastoma.
Totaro F, Cimmino F, Pignataro P, Acierno G, De Mariano M, Longo L, Tonini GP, Iolascon A, Capasso M. Totaro F, et al. Among authors: cimmino f. PLoS One. 2013 Oct 21;8(10):e76810. doi: 10.1371/journal.pone.0076810. eCollection 2013. PLoS One. 2013. PMID: 24204677 Free PMC article.
Association of PARP1 polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma.
Avitabile M, Lasorsa VA, Cantalupo S, Cardinale A, Cimmino F, Montella A, Capasso D, Haupt R, Amoroso L, Garaventa A, Quattrone A, Corrias MV, Iolascon A, Capasso M. Avitabile M, et al. Among authors: cimmino f. J Cell Mol Med. 2020 Apr;24(7):4072-4081. doi: 10.1111/jcmm.15058. Epub 2020 Feb 27. J Cell Mol Med. 2020. PMID: 32103589 Free PMC article.
66 results